Research schedules for sermorelin differ. Selected pediatric and older-men studies used nightly injections [4] [5], while Corpas studied twice-daily GHRH(1-29) [3]. These protocols do not establish a universal bedtime, fasting or five-nights-a-week rule for current compounded preparations. Ask the prescriber how the exact product’s instructions are supported.
Selected studies used different schedules
Sermorelin was given once a day at bedtime in the 1996 Geref study of 110 children with growth-hormone deficiency [4]. A 1997 study had 11 healthy men aged 64 to 76 inject it themselves every night for six weeks [5]. A 1997 study of a one-amino-acid analog had 19 older adults inject it nightly at 9 p.m. [6].
These are selected protocols, not the whole GHRH literature. They describe researcher choices rather than establish the schedule that best suits an individual patient.
| Study | Who | People | Timing | How often | Length |
|---|---|---|---|---|---|
| Thorner 1996 [4] | Children with growth-hormone deficiency, not yet treated | 110 | Bedtime | Once a day | Up to 1 year |
| Vittone 1997 [5] | Healthy men aged 64 to 76 with low IGF-1 | 11 | Nightly, at home | Once a night | 6 weeks |
| Khorram 1997 (analog) [6] | Healthy adults aged 55 to 71 (10 women, 9 men) | 19 | Nightly at 9 p.m. | Once a night | 16 weeks, after 4 weeks of placebo |
| Corpas 1992 [3] | Older men; younger baseline comparators | 10 treated; 9 comparators | Two daily administrations; dose-order comparison | Twice daily | Two 14-day courses, separated by 14 days untreated |
| Koutkia 2004 [11] | Men with HIV lipodystrophy; Geref versus placebo | 31 randomized | Every twelve hours | Two administrations daily | 12 weeks |
The Khorram study used [Nle27]GHRH(1-29), a close analog, not sermorelin itself.
What the nighttime studies measured
Night dosing lines up with the body's own largest growth-hormone release, which comes in the early hours of sleep. The 1997 adult study measured growth hormone every 20 minutes from 8 p.m. to 8 a.m. Nightly sermorelin raised the average night-time release and the size of the peaks [5].
The analog study saw the same pattern. A 9 p.m. injection released growth hormone within 10 minutes, and the rise lasted about 2 hours [6]. This protocol did not compare morning with bedtime and does not establish the best time for a current compounded preparation.
That is a lab result. The same study found no change in IGF-1, weight or DEXA measures of muscle and fat after six weeks [5]. Whether sermorelin does what it's sold for is a separate question, covered in does sermorelin work.
Morning treatment: what do the reviewed trials establish?
The reviewed studies do not establish that a morning routine is better or worse than bedtime for adult wellness outcomes. Corpas used two daily administrations [3]. Bueno’s pediatric priming study included a morning diagnostic test after several days of GHRH exposure; that does not establish a routine adult morning regimen [7].
If a prescriber suggests a morning schedule, that's a judgment call. Ask why they chose it and what they'll watch for.
Should you eat first? Ask your prescriber
The selected chronic studies do not establish a meal-timing rule for a current compounded preparation. Ask whether food timing matters for your exact form and why; an injection and an oral preparation need separate evidence.
Frequency differed between studies
The 1996 pediatric study and the 1997 adult study both gave sermorelin once a day, by injection under the skin [4] [5]. No current label sets a frequency, so your prescriber sets your schedule.
The selected chronic protocols above used injections; older intranasal GHRH experiments also studied hormone and sleep responses. Those findings do not validate current oral or nasal products, as explained in the route-specific evidence review.
Duration: selected short studies do not establish long-term safety
Selected older-adult reports ran six weeks for GHRH(1-29) [5] and sixteen weeks for a norleucine27 analog [6]. Other protocols and populations differ. These observations do not establish a maximum safe duration, a predictable benefit timeline or long-term safety for a current compounded preparation.
Why no official schedule exists
Sermorelin was once FDA-approved as Geref. The maker asked FDA to withdraw its approvals, and FDA did so in 2009 [9]. In March 2013, FDA said Geref was not withdrawn from sale for reasons of safety or effectiveness [8].
DailyMed carries no current sermorelin label as of this update [10]. Historical Geref instructions do not become instructions for today’s compounded preparation. The full status is on is sermorelin FDA approved.
| Question | Official FDA source? | Where the answer comes from |
|---|---|---|
| Time of day | No | Your prescriber |
| How often | No | Your prescriber |
| How long to stay on it | No | Your prescriber |
| With or without food | No | Your prescriber |
| Which kind of pharmacy can make it | Yes: FDA's 503A and 503B compounding rules | The dispensing pharmacy |
Can women take sermorelin? The trials included few women
The former Geref approval was for children and wasn't limited by sex. The adult analog study included 10 women among its 19 people [6]. The six-week sermorelin study enrolled men only [5].
The reviewed sources do not establish safety or an appropriate treatment schedule during pregnancy. Pregnancy, breastfeeding or plans to become pregnant belong in the prescribing discussion.
The cited analog study reported sex-specific findings. Both sexes had higher growth hormone and IGF-1. Lean body mass rose in the men only, and the women's body composition didn't change [6]. With 10 women in one study, that is too little to plan around.
Questions to ask your prescriber
- What time of day do you want me to take it, and why that time?
- Should I take it with or without food?
- How often, and what is that schedule based on?
- How long will I stay on it, and when will we recheck IGF-1 or other labs?
- Which pharmacy makes it, and is it a 503A or a 503B pharmacy?
Other short adult protocols answer narrower questions
Corpas and colleagues studied ten older men through two 14-day courses of GHRH(1-29), in randomized dose order, with nine younger men providing a baseline comparison. The higher regimen increased growth-hormone and IGF-I measures; fasting glucose, urinary C-peptide, blood pressure and routine chemistry were unchanged [3]. This is another adult exposure study, not proof of improved body composition, long-term safety or a schedule for current compounded products.
The broader GHRH sleep literature also prevents a blanket claim that sleep was never studied. Kern and colleagues found no sleep change during an overnight GHRH infusion experiment in ten men [1]. Perras and colleagues used intranasal GHRH in a crossover study of twelve younger and eleven older men and reported increases in REM and slow-wave sleep [2]. These acute, route-specific experiments do not establish the long-term benefits of commercially offered compounded sermorelin or a preferred injection timetable.